ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain

We remain dedicated to providing flexible treatment options for women and look forward to further development of linzagolix in the endometriosis indication.